# CJC-1295 No DAC

> Evidence tier C — Animal data · GH & Growth · reviewed 2026-11-08
> Source page: https://peptidemeta.com/p/cjc-1295-no-dac/

Also known as: Mod GRF (1-29), Modified GRF 1-29, Tetrasubstituted GRF(1-29)

## Quick answers

**What is CJC-1295 No DAC?**

A modified GRF (1-29) analog without the drug-affinity complex, providing a shorter-acting but more pulsatile GH release pattern that mimics natural physiology. Same compound as Modified GRF(1-29) (tetrasubstituted GHRH 1-29); "CJC-1295 no DAC" is a vendor name.

**How strong is the evidence for CJC-1295 No DAC?**

Tier C (animal data) on the peptidemeta evidence scale. Published data are mostly preclinical; no completed human trials of this compound were found.

**Is CJC-1295 No DAC FDA-approved?**

No. CJC-1295 No DAC is not approved by the FDA for any use.

**Is CJC-1295 No DAC banned in sport?**

Yes. CJC-1295 No DAC is prohibited in sport by the World Anti-Doping Agency under S2 (peptide hormones, growth factors, related substances and mimetics).

**How does CJC-1295 No DAC work?**

CJC-1295 no DAC (modified GRF 1-29) binds the GHRH receptor on pituitary somatotrophs, stimulating GH release via adenylyl cyclase/cAMP signaling. Without the DAC moiety it has a half-life of approximately 30 minutes, producing a sharp GH pulse that closely mimics the natural pulsatile secretion pattern.

**What is known about the safety of CJC-1295 No DAC?**

Well-tolerated in clinical settings. Short half-life means lower risk of sustained IGF-1 elevation compared to DAC variant.

## Key facts

- **Evidence tier:** C (Animal data)
- **FDA:** not approved
- **WADA:** prohibited (S2)
- **Peptide:** yes
- **Routes studied:** Subcutaneous, Intramuscular

## Overview

A modified GRF (1-29) analog without the drug-affinity complex, providing a shorter-acting but more pulsatile GH release pattern that mimics natural physiology.

## Mechanism

CJC-1295 no DAC (modified GRF 1-29) binds the GHRH receptor on pituitary somatotrophs, stimulating GH release via adenylyl cyclase/cAMP signaling. Without the DAC moiety it has a half-life of approximately 30 minutes, producing a sharp GH pulse that closely mimics the natural pulsatile secretion pattern.

## Effects reported in research

_Reported outcomes, not promises; see the evidence tier._

- Pulsatile growth hormone release
- Improved body composition
- Better sleep architecture
- Synergistic effects when paired with a GHRP

## Safety & unknowns

Well-tolerated in clinical settings. Short half-life means lower risk of sustained IGF-1 elevation compared to DAC variant. Common side effects: flushing, headache, dizziness. Not FDA-approved.

## Studies

- Teichman SL, et al. (2006). *Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults*. Journal of Clinical Endocrinology and Metabolism. Clinical trial. https://pubmed.ncbi.nlm.nih.gov/16352683/
  Key study on the CJC-1295 molecule platform demonstrating its GH-stimulatory properties in humans.

## Status sources

- [PubMed: tetrasubstituted GRF(1-29)](https://pubmed.ncbi.nlm.nih.gov/?term=modified+GRF+1-29)
- [WADA 2026 Prohibited List](https://www.wada-ama.org/en/prohibited-list)

---

Educational reference only — not medical advice. No dosing information is published. Tiers rate the strength of published evidence, not effectiveness or safety.